ATE273713T1 - Fas-antagonist für die prophylaxe oder therapie von gvhd - Google Patents

Fas-antagonist für die prophylaxe oder therapie von gvhd

Info

Publication number
ATE273713T1
ATE273713T1 AT97909714T AT97909714T ATE273713T1 AT E273713 T1 ATE273713 T1 AT E273713T1 AT 97909714 T AT97909714 T AT 97909714T AT 97909714 T AT97909714 T AT 97909714T AT E273713 T1 ATE273713 T1 AT E273713T1
Authority
AT
Austria
Prior art keywords
gvhd
prophylaxis
therapy
fas antagonist
present
Prior art date
Application number
AT97909714T
Other languages
English (en)
Inventor
Shigekazu Nagata
Takehiro Yatomi
Takashi Suda
Original Assignee
Mochida Pharm Co Ltd
Osaka Bioscience Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mochida Pharm Co Ltd, Osaka Bioscience Inst filed Critical Mochida Pharm Co Ltd
Application granted granted Critical
Publication of ATE273713T1 publication Critical patent/ATE273713T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
AT97909714T 1996-10-31 1997-10-31 Fas-antagonist für die prophylaxe oder therapie von gvhd ATE273713T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP29045996 1996-10-31
JP35171896 1996-12-27
JP26252197 1997-09-26
PCT/JP1997/003978 WO1998018487A1 (en) 1996-10-31 1997-10-31 Prophylactic/remedial agent

Publications (1)

Publication Number Publication Date
ATE273713T1 true ATE273713T1 (de) 2004-09-15

Family

ID=27335136

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97909714T ATE273713T1 (de) 1996-10-31 1997-10-31 Fas-antagonist für die prophylaxe oder therapie von gvhd

Country Status (8)

Country Link
US (1) US7128905B2 (de)
EP (2) EP0992243B1 (de)
JP (1) JP4339405B2 (de)
AT (1) ATE273713T1 (de)
AU (1) AU4726797A (de)
CA (1) CA2270423C (de)
DE (1) DE69730358T2 (de)
WO (1) WO1998018487A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69935662D1 (de) 1998-02-06 2007-05-10 Mochida Pharm Co Ltd Mittel zur prävention/behandlung entzündlicher darmerkrankungen
DE69932434D1 (de) 1998-05-29 2006-08-31 Mochida Pharm Co Ltd Prophylaxe und Behandlung von autoimmunen Entmyelinisierungserkrankungen durch Fas-antagonisten
WO2004022545A1 (ja) * 2002-09-06 2004-03-18 Mitsubishi Pharma Corporation 移植臓器保護剤
EP1447093A1 (de) 2003-02-14 2004-08-18 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Inhibition des CD95 Ligand/Rezeptorsystems zur Behandlung neurologischer Störungen und Verletzungen
WO2004085479A2 (en) 2003-03-26 2004-10-07 Apogenix Gmbh Treatment of viral infections
EP1839675A1 (de) * 2004-09-28 2007-10-03 Japan Science and Technology Agency Neues verfahren zum schutz vor ischämischer kardiopathie
US20090156488A1 (en) * 2007-09-12 2009-06-18 Zensun (Shanghai) Science & Technology Limited Use of neuregulin for organ preservation
US20110189194A1 (en) * 2008-07-14 2011-08-04 Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts Use of cd95 inhibitors for the treatment of inflammatory disorders
JP2012501456A (ja) * 2008-08-28 2012-01-19 アスチュート メディカル，インコーポレイテッド 腎損傷および腎不全の診断および予後のための方法および組成物
AU2010223569A1 (en) * 2009-03-12 2011-11-03 Imed Ab Human antibodies against human Fas and their use
AU2013291982B2 (en) * 2012-07-18 2017-01-12 Apogenix Ag Shortened CD95-Fc variants
WO2021183845A1 (en) * 2020-03-13 2021-09-16 Janssen Biotech, Inc. Materials and methods for modulating delta chain mediated immunity
US12076413B2 (en) 2020-10-28 2024-09-03 Janssen Biotech, Inc. Compositions and methods for modulating delta gamma chain mediated immunity

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ275711A (en) * 1993-10-14 1998-03-25 Immunex Corp Monoclonal antibodies and binding proteins which bind to human fas antigen (nerve growth factor/tumour necrosis factor receptor type)
US5801154A (en) * 1993-10-18 1998-09-01 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of multidrug resistance-associated protein
US5663070A (en) * 1993-11-15 1997-09-02 Lxr Biotechnology Inc. Recombinant production of a soluble splice variant of the Fas (Apo-1) antigen, fas TM
ATE387458T1 (de) 1994-01-07 2008-03-15 Mochida Pharm Co Ltd Fas-antigenbindender ligand
JPH07289266A (ja) * 1994-04-21 1995-11-07 Mochida Pharmaceut Co Ltd ヒトＦａｓ抗原バリアント及びそれをコードする新規ＤＮＡ
US5759536A (en) * 1994-05-27 1998-06-02 University Technology Corporation Use of fas ligand to supress T-lymphocyte-mediated immune responses
JP3055006B2 (ja) * 1994-09-27 2000-06-19 参天製薬株式会社 リウマチ治療剤
US5776718A (en) * 1995-03-24 1998-07-07 Arris Pharmaceutical Corporation Reversible protease inhibitors
AU6091496A (en) * 1995-06-07 1996-12-30 Chiron Corporation Antibodies to fas antigen capable of inhibiting apoptosis
WO1997012632A1 (en) * 1995-10-05 1997-04-10 Tkb Associates Limited Partnership Methods for treatment of diseases associated with a deficiency of fas ligand activity
JPH09110722A (ja) * 1995-10-20 1997-04-28 Toray Ind Inc 抗腫瘍活性物質の腫瘍細胞内導入用イムノリポソーム及びその調製法
JPH09124509A (ja) * 1995-10-27 1997-05-13 Sumitomo Electric Ind Ltd 肝炎治療剤
AU2527397A (en) * 1996-03-13 1997-10-01 Protein Design Labs, Inc. Fas ligand fusion proteins and their uses
US6007995A (en) * 1998-06-26 1999-12-28 Isis Pharmaceuticals Inc. Antisense inhibition of TNFR1 expression

Also Published As

Publication number Publication date
US7128905B2 (en) 2006-10-31
EP0992243A4 (de) 2000-04-12
WO1998018487A1 (en) 1998-05-07
JP4339405B2 (ja) 2009-10-07
EP0992243B1 (de) 2004-08-18
DE69730358T2 (de) 2004-12-30
EP1449539A2 (de) 2004-08-25
EP0992243A1 (de) 2000-04-12
CA2270423A1 (en) 1998-05-07
US20030109416A1 (en) 2003-06-12
AU4726797A (en) 1998-05-22
DE69730358D1 (de) 2004-09-23
CA2270423C (en) 2009-09-15

Similar Documents

Publication Publication Date Title
NZ335981A (en) Ketobenzamides as calpain inhibitors
DE68929460D1 (de) Substituierte Phenylpyrimidine Derivate, für die Behandlung oder Prevention von ZNS-Erkrankungen
DE69730358D1 (de) Fas-Antagonist FÜR DIE PROPHYLAXE ODER THERAPIE VON GVHD
DE69510696D1 (de) 2-(2-amino-3-methoxyphenyl)-4-oxo-4h-(1)-benzopyran für die behandlung von proliferativer erkrankungen
CA2241981A1 (en) Method of inhibiting photoaging of skin
DE3579113D1 (de) Zusammensetzungen zur milderung, behandlung und bestimmungung von arthritschen krankheiten und aehnlichen zustaenden.
ES2166783T3 (es) Factor viii activado utilizado como agente terapeutico y metodo para el tratamiento de la deficiencia de factor viii.
ES2038609T3 (es) 4,5-dihidroisoxazol, 3,5 disustituido como inhibidores de transglutaminasa.
ES2164916T3 (es) Tratamiento de la esclerosis multiple.
ATE321548T1 (de) Verwendung von statin zur behandlung von hauterkrankungen
DE3587741D1 (de) Behandlung von Hautkrankheiten.
NO990433D0 (no) Nye forbindelser og blandinger for behandling av sykdommer i forbindelse med tryptase-aktivitet
EP0610368A4 (de) Behandlung von akne oder von folliculitis barbae.
AU4089889A (en) Method of treating skin injuries using thromboxane a2 receptor antagonists
MX9703693A (es) Tratamiento profilactico de dermatitis alergica por contacto.
DK71387D0 (da) Terapeutisk middel til behandling af psoriasis
ZA898605B (en) Compositions for topical treatment of skin diseases
ATE271873T1 (de) Verwendung von glukosamin und glukosaminderivaten zur schnellen linderung von juckreiz oder lokalisiertem schmerz
AU4376396A (en) Use of andrographolide compounds to treat or prevent pathogenicity of diseases
FR2524486B1 (fr) Souches de champignon pour le traitement des maladies fongiques des plantes et utilisation de ces souches
BE884756A (fr) Composition dermatologique pour le traitement des maladies de la peau, accompagnees d'une proliferation cellulaire, telles que le psoriasis
NO984245D0 (no) Nasal administrasjon av midler for behandling av emesis med forsinket begynnelse
GB2163051A (en) Medicinal composition for the treatment or prevention of acne by topical application
DE59900286D1 (de) Verwendung von sphingosin-1-phosphat, sphingosin-1-phosphat-derivaten und/oder deren gemische zur behandlung von entzündlichen hautkrankheiten
NO962221D0 (no) Anvendelse av dimeticon for behandling av konstipasjon

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties